Novel Capital Review: Fees, Terms & Top Alternatives

How Novel Capital Works

Novel's flagship product, UpFront Capital, is structured as a draw-down credit facility. A founder is approved for a facility size of 10–40% of ARR (between $100K and $5M total), draws capital as needed over a 12-month draw window, and pays interest only on the drawn balance. The monthly payment is fixed in dollar terms but scales upward as additional capital is drawn or as ARR grows. Repayment runs from 3 to 36 months. There are no warrants, no equity, no board seats, no personal guarantees, and no prepayment penalties per Novel's public marketing.

Novel's second product, Flow Financing (formerly Short-Term Capital), is an invoice-receivable line: founders draw against eligible invoices ($100K minimum invoice size, $25K minimum draw), repay 5% of the drawn amount at day 30, 5% at day 60, and the balance at day 90. The total fee is a flat 5% of the amount drawn.

Eligibility for UpFront Capital per Novel's public product page requires $350,000+ in annual revenue, 10%+ year-over-year revenue growth, 24+ months in business, B2B SaaS or tech with recurring revenue, and US-based operations. Flow Financing requires $1M+ ARR. Novel underwrites continuously through its Capital Intelligence dashboard, which ingests billing, accounting, and banking data via direct integrations rather than monthly PDF reporting.

By contrast, Founderpath uses automated billing, accounting, and banking integrations to underwrite and fund in under 24 hours on both its Revenue Purchase Agreement and Term Loan, with a $100,000 annual revenue minimum, no growth covenant, and SaaS-specific underwriting that surfaces published rates before any sales conversation.

Why Founders Look for Novel Capital Alternatives

• 1.Limited public pricing. Novel does not publish a rate card on the UpFront Capital product page itself. One Novel blog post discloses an 8% one-time fee on monthly contracts (≈ 18% APR over 12 months); CEO Keith Harrington separately cited 1.5x–1.75x payback over 3–4 years on the Cremades podcast. Outside those two sources, payback multiples, revenue percentages, and term lengths are quoted individually per deal. Founderpath publishes its starting rates on every product page: 7% flat discount fee on the RPA, 14% APR on the Term Loan.
• 2.$350K minimum revenue. Novel's published qualification on the UpFront Capital product page is $350K annual revenue. Founderpath starts at $100K in annual revenue, which opens the entire early-stage SaaS segment.
• 3.10% YoY growth requirement. Novel requires 10%+ year-over-year revenue growth at the qualification stage. Founderpath has no growth covenant on either the RPA or Term Loan products — stable, cash-flow-positive SaaS businesses qualify.
• 4.30-day funding timeline. Novel publicly states “capital delivered in 30 days or less” once approved. Founderpath funds in under 24 hours after billing, accounting, and banking integrations are connected — a one-month difference in time-to-cash that materially affects whether you can meet a vendor, payroll, or growth deadline.
• 5.US-only. Novel publicly requires US-based operations. European, LatAm, and APAC SaaS founders are not eligible. Founderpath funds SaaS companies worldwide.
• 6.36-month maximum term. Novel UpFront Capital caps repayment at 36 months. Founderpath's Term Loan extends to 48 months, materially lowering monthly payments on the same principal — particularly meaningful for founders deploying capital into longer-payback growth investments.
• 7.Equity-bridge positioning. Novel's VentureMatch product actively brokers founders to 100+ partner VC firms. That positions Novel as a stepping-stone toward equity rather than a long-term non-dilutive partner. Bootstrapped founders who do not intend to raise equity may find Founderpath's positioning a stronger fit.

Top 5 Novel Capital Competitors and Alternatives in 2026

The main companies founders compare with Novel Capital include Founderpath, Capchase, Lighter Capital, SaaS Capital, and Decathlon Capital. Below we compare core terms.

Founderpath is the only Novel Capital alternative on this list with a $100K revenue minimum, sub-24 hour funding, and worldwide availability — and offers both a revenue purchase agreement and a term loan with no closing costs or origination fees.

Many founders comparing Novel Capital also evaluate Founderpath vs Capchase and Founderpath vs Lighter Capital.

Pros and Cons of Novel Capital

Novel Capital Pricing Explained

Novel does not publish a rate card on the UpFront Capital product page itself. The most direct public statement on cost comes from Novel's own blog post “When You Should Use UpFront Capital To Get Funding”, which describes the product as “a one-time fee of 8% of your monthly contracts” “equivalent to an 18% APR.” The 8% fee / 18% APR figures are independently restated in a March 2022 Innovative Finance Playbook case study, which adds the explicit “12-month payment schedule” context. Note that the 18% APR figure is consistent with that 12-month schedule; longer terms or larger payback multiples produce higher implied APR.

A second pricing anchor comes from Co-Founder Keith Harrington on the Alejandro Cremades interview (~2024), where Harrington described Novel's blended deals as “1.5x to 1.75x over 3 to 4 years.” This is the closest CEO-cited multiple range for Novel's longer-term facilities and aligns with David Teten's 2019 RBI investor survey (also published on TechCrunch), which quoted Novel Growth Partners' legacy fund directly: “4% to 8% of monthly revenue… return cap of 1.5–2.2x over up to 5 years.” The two on-the-record sources bracket Novel's practical pricing range.

Novel's legacy RevShare Capital product is described in Novel's own educational pages as a 4–9% royalty on monthly gross cash receipts with returns capped at 1.2x–1.9x of capital invested. RevShare appears largely retired in favor of UpFront Capital but the cap range remains a Novel-disclosed pricing band. For broader industry context, RBF benchmarks from Decathlon Capital, SaaS Capital, and Bigfoot Capital consistently place the RBF total-return multiple at 1.5x–3.0x with 20–40% IRR — putting Novel's 1.5x–2.2x band in the middle of the standard RBF range, not at a discount.

Translating Harrington's 1.5x–1.75x range to implied APR depends on term length within the 3–4 year band he quoted. On a 36-month term — Novel's currently-published UpFront max and the floor of Harrington's range — a 1.5x payback maps to an implied APR of approximately 28.6%, 1.65x ≈ 36.1%, 1.75x ≈ 40.9%. On a 48-month term — the 4-year upper bound of Harrington's quote, which exceeds the current published UpFront max and applies to extended or legacy facilities — a 1.5x payback maps to ≈ 21.5%, 1.65x ≈ 27.2%, 1.75x ≈ 30.8% (longer terms mean lower implied APR for the same multiple). We do not present APRs for 12-month or 24-month terms applied to these multiples because Novel never quoted those (multiple, term) combinations: the 12-month UpFront product is separately priced at 8% / 18% APR (1.08x payback), and Harrington's 1.5x–1.75x quote explicitly covers the 3–4 year band, not 12 or 24 months. Forcing his multiples onto a 12-month term would produce a fabricated ≈ 82% APR figure that misrepresents what Novel actually charges. The conversion uses standard present-value methodology consistent with Lighter Capital's effective-APR formula and Forward Financing's RBF cost-comparison framework (which similarly arrives at ~35% APR on a 1.2x factor at standard amortization). Implied APR rises sharply on shorter terms because the same multiple is paid back over fewer months — a key reason RBF can become expensive when revenue grows fast and accelerates repayment, a point Decathlon Capital and re:cap both highlight in their own RBF educational content.

Founderpath's Revenue Purchase Agreement starts from a 7% flat discount fee over terms up to 36 months with no closing costs. The Term Loan starts at 14% APR with terms up to 48 months and optional interest-only periods. Both products fund in under 24 hours with no growth covenants.

Is Founderpath Cheaper Than Novel Capital?

Direct comparison requires the actual term sheet from Novel, which is not publicly disclosed. The honest answer depends on which Novel product you take. Below we compare a $1,000,000 facility under the two pricing scenarios Novel itself has put on the record.

Scenario 1: Novel's 12-month UpFront schedule (1.08x payback / 8% one-time fee / ≈18% APR per Novel's blog).

• Novel total repayment $1,080,000, monthly payment $90,000, implied APR ≈ 14.5%. Founderpath Term Loan at 14% APR over 12 months totals approximately $1,077,000 with monthly payments of $89,787 — essentially equivalent on total cost. Founderpath Term Loan at 14% APR over 48 months totals approximately $1,312,000 with monthly payments of $27,326 — Novel is cheaper on total cost at the 12-month schedule (~$232,000 less than the longer-term FP option), but FP's longer term cuts monthly payments by roughly two-thirds.

Scenario 2: Novel's multi-year UpFront facility (1.5x–1.75x payback over 3–4 years per CEO Keith Harrington on the Cremades interview).

• 1.5x payback over 36 months: Novel total repayment $1,500,000, monthly payment $41,667, implied APR ≈ 28.6%. Founderpath Term Loan at 14% APR over 48 months produces total repayment of approximately $1,312,000 with monthly payments of $27,326 — roughly $188,000 less in total cost and $14,341 lower per month.
• 1.75x payback over 36 months: Novel total repayment $1,750,000. Founderpath Term Loan at 14% APR over 48 months still totals approximately $1,312,000 — a difference of approximately $438,000 in total cost on the same principal.

Honest read: Novel's 12-month UpFront product is competitive with Founderpath on a 12-month total-cost basis. The cost gap opens up on multi-year deals — at every scenario inside Harrington's public 1.5x–1.75x range over 36 months Founderpath's Term Loan produces meaningfully lower total cost and lower monthly payments. The non-cost differences (Founderpath's $100K minimum vs Novel's $350K, no growth covenant vs 10% YoY required, worldwide vs US-only, 48-month max vs 36-month) apply across both scenarios.

Use the cost calculator below to compare your specific loan amount and assumed payback multiple against Founderpath's monthly payment.

Novel Capital Funding, Valuation & Investors

Novel Capital is a privately held company and has not disclosed an official valuation. Per public press releases and Co-Founder Keith Harrington's on-the-record statements, Novel has raised $130M+ in combined equity and debt across three rounds since founding as Novel Growth Partners in 2017 (rebranded to Novel Capital in 2021).

Per Co-Founder Keith Harrington on the Alejandro Cremades interview, the bulk of Novel's capital stack is debt — “about $120 million in debt to deploy” versus “a little over $15 million in equity.” That structure is consistent with a fintech-platform / credit-facility model rather than a traditional GP/LP fund — Novel raises warehouse-style debt facilities to fund customer advances, with thin equity to cover platform operations. The May 2024 Pre-Series A was earmarked for the Capital Intelligence platform (the SaaS dashboard, valuation tools, and VentureMatch product). The 2022 round triggered the public rebrand from Novel Growth Partners to Novel Capital.

Notable investors across rounds: Community Investment Management (CIM), IGNIA Partners, Ulu Ventures (returning investor in 2022 and 2024), MatterScale Ventures (returning), Nueterra Capital, Tenzing.vc, Gaingels, KCRise Fund, and Edovate Capital. Novel does not appear to have raised from Tier 1 SaaS-focused investors (Sequoia, a16z, Bessemer, Accel) — the cap table skews toward fintech-credit and Midwest regional VCs, consistent with Novel's Kansas HQ and credit-facility business model.

Founderpath vs Novel Capital: Which Is Right for You?

Novel Capital is a legitimate, well-capitalized growth lender with 7+ years of operating history, 150+ funded SaaS customers, $100M+ deployed, and a 4.8/5 Trustpilot rating. If you operate a US-based B2B SaaS business with $350K+ in revenue and 10%+ year-over-year growth, want a draw-down credit facility (rather than a single lump sum), and value access to a VC matchmaking product, Novel is worth evaluating.

However, for SaaS founders who want lower minimums, faster funding, no growth covenant, published pricing, longer terms, or worldwide availability, Founderpath is the stronger choice. Founderpath starts at $100K in annual revenue (vs $350K), funds in under 24 hours (vs 30 days), publishes starting rates (vs none), extends terms to 48 months (vs 36 months on Novel UpFront), and has no growth covenant.

The practical decision for most SaaS founders comes down to five questions: How much revenue do you have? How fast do you need to close? Is your business growing 10%+ year-over-year? Are you US-based? And do you want a published rate before applying? If your revenue is under $350K, if growth is flat or under 10%, if you need to close in under a week, if you operate outside the US, or if you want to compare published rates before applying, Founderpath is likely the better fit.

Both providers are non-dilutive, do not require personal guarantees, and do not take warrants or equity. Founderpath wires funds in under 24 hours; Novel publicly states 30 days or less. Founderpath publishes a starting rate; Novel does not on its current UpFront Capital product. For most SaaS founders, Founderpath offers more accessible terms across the comparison dimensions that matter most.